Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance - Wikidata - awgldk - TriplyDB

Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance

Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance

http://www.wikidata.org/entity/Q28303717

about

CAS proteins in normal and pathological cell growth control Targeting Src family kinases in anti-cancer therapies: turning promise into triumph Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines NSP-CAS Protein Complexes: Emerging Signaling Modules in Cancer Loss of AND-34/BCAR3 expression in mice results in rupture of the adult lens Embryonal Fyn-associated substrate (EFS) and CASS4: The lesser-known CAS protein family members Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus.High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells.Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes.Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.Genome-wide DNA methylation profiling reveals parity-associated hypermethylation of FOXA1.Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study.MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells.Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis.The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib KLF6-SV1 drives breast cancer metastasis and is associated with poor survival Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response.Bisindole-PBD regulates breast cancer cell proliferation via SIRT-p53 axis.Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer TLE3 as a candidate biomarker of response to taxane therapy.The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells.CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance Nuclear factor-ĸB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells.Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells.Immunohistochemical expression of GPR30 in breast carcinoma of Egyptian patients: an association with immunohistochemical subtypes.The transcriptional co-repressor TLE3 suppresses basal signaling on a subset of estrogen receptor α target genes.

P2860

Q24630247-01D494FB-B8EF-4AF2-BB73-8313F9BAF56C Q27025646-C1106BCD-D9BE-4FB3-9D31-83FAC7815DB8 Q28259553-54702C34-0147-48B1-87F4-E3CB4D166369 Q28281166-B8D35559-B149-473A-9B19-13B5714FA8A3 Q28510147-10C2AD4E-582A-4827-818F-5712580E9E72 Q28646036-475FABA3-B9EF-4636-A377-27BCE2BF2CD3 Q30408424-7C5AC7D9-ECC6-4D73-95C9-B2FE4AAE4DCD Q33528957-5F134C64-1CD7-420B-A417-48A66EF2774D Q33612070-DD5DEF91-7A7D-4726-BDD4-D7EEEF42515A Q33641475-838FBEA1-14FE-4F7A-AAA6-C4DA14E9281C Q33739228-371A5599-9B61-48F5-8C35-F208234F96CD Q33954542-AB442D7F-1B4E-4ABB-8E96-4A8940A1215D Q33958257-36CB91CD-4C98-4FF8-8F5A-6F8BBB3632AD Q34255976-7EEB948E-EAEE-4795-AB16-0569AE7DA3EC Q34273001-FB86EE3E-2695-435C-B158-3BBE71E9944F Q34371359-9815BCE2-31E8-4B0D-913E-FB812DB5CF34 Q34387890-A17D9B66-F91B-4A01-A01F-06DA65730E02 Q34613612-90E4FA1D-65E0-479D-98DC-8C3C30FB2DFF Q34946215-421B8853-14E5-40C7-A3C5-93959DE542D9 Q35118166-FF5ADAEC-F571-43FD-A6AC-B987D9AA8936 Q35758871-7445654D-170D-428F-A69D-006F8AB3D69B Q35906736-A187D151-1B98-4310-B05A-37F70BD130A9 Q35906949-F1AF597F-3366-483E-AA5D-3E9BED5756C1 Q36110285-30857371-C3B7-4765-B4B8-96FB9F9DA82A Q36135818-2F184A53-5586-4F88-875C-6B6A429033AB Q36299102-8A362827-4AEF-4C65-85B8-7D8EB8DE3D1A Q36324431-1861AFF7-6EE1-44CF-A4BD-7991398D4D6A Q36455407-7FF13713-7884-4B2D-8BBF-7D2C765F711A Q36838991-7C2AF867-0227-43D2-9BF6-3F9639A342FC Q37137065-DC5DC926-B80F-4408-99FD-6BBCF58841CF Q37208764-CA558A1B-781E-44FF-B72F-80944B4BCF13 Q37298189-727C8B63-DB8D-40D3-92A6-DFF16DEEF27A Q37457732-4CA0AD3E-DDA4-46A7-B917-43D51A44F39E Q37558869-035C2810-E9A5-4BB3-8A55-BE6E266DACAD Q37587494-9D8AFBBB-30F1-40CD-831F-DBB770C9F5B1 Q37634494-B8CCF372-64DD-429A-84D8-8E2B95481554 Q37689922-D76EC46C-81AC-472D-B0A8-7B0E73598BAA Q37696230-757AF7ED-C6CE-4359-8D48-A085FB4D207B Q38392548-78ED6AD6-AFF5-4B89-8281-1B224467D2D1 Q38956394-30C3321D-DFCF-42D0-9637-DF99FF3A0810

P2860

Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance

http://www.wikidata.org/entity/Q28303717

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Relevance of breast cancer ant ...... ssion and tamoxifen resistance

@ast

Relevance of breast cancer ant ...... ssion and tamoxifen resistance

@en

Relevance of breast cancer ant ...... ssion and tamoxifen resistance

@nl

type

label

Relevance of breast cancer ant ...... ssion and tamoxifen resistance

@ast

Relevance of breast cancer ant ...... ssion and tamoxifen resistance

@en

Relevance of breast cancer ant ...... ssion and tamoxifen resistance

@nl

prefLabel

Relevance of breast cancer ant ...... ssion and tamoxifen resistance

@ast

Relevance of breast cancer ant ...... ssion and tamoxifen resistance

@en

Relevance of breast cancer ant ...... ssion and tamoxifen resistance

@nl

P1433

Q28303717-5822AD93-8BB1-4C97-89AD-211BD48CB586

P1476

Q28303717-2F519808-72FE-4B09-8398-47D9BD3CA29F

P2093

Q28303717-21F227D2-782E-4C81-BC37-F85B5C15DD75

Q28303717-58A277CF-EA90-48A1-B5F8-6B5BA240F7C4

Q28303717-619DB76D-4B8F-4587-AC86-9BAF3D2DF6C7

Q28303717-646A1F31-DED3-4FAC-BFC7-BAC3B093E58C

Q28303717-8CC9DD11-6211-4671-8839-8C7AD5C25CD1

Q28303717-A0E01ED2-EC3F-4D80-AFD7-6C69E084FB32

Q28303717-A17EAA94-EE9F-4F6D-B6EF-FE98D7CB526A

Q28303717-A9257B58-787C-4BA0-8A8F-88110FFF6194

Q28303717-CC7C108B-07BD-4FB5-A17C-850176716884

P304

Q28303717-6E9F7A93-7AD0-4AD7-A7C2-DB5000A71F57

P31

Q28303717-36FB11DE-FF79-4D09-8D54-F00FBF51FFCA

P3181

Q28303717-03CC81AB-D106-486B-A253-C97F5EDB8F00

P356

Q28303717-7A92F476-A48D-4192-95CF-56CC3B36ADA1

P407

Q28303717-935925AF-EC57-4729-BF42-EB7130B87DCA

P433

Q28303717-F94DEF58-B25F-403E-96D7-81244AE1CA36

P478

Q28303717-BC911150-77BA-4598-B64D-DF32DBA833DE

P577

Q28303717-6914A908-5518-4E03-B58F-C6C6FB680952

P5875

Q28303717-28CAD7FA-C44F-4FD9-B907-6D08CB144F52

P698

Q28303717-A22037C4-6AD8-45D7-BC49-F8A47D76E70F

P921

Q28303717-7E7EEE56-8DE8-467B-8ED3-8D5AD6286494

P3181

P356

JCO.2008.17.1462

P1433

Journal of Clinical Oncology

P1476

Relevance of breast cancer ant ...... ssion and tamoxifen resistance

@en

P2093

Anieta M Sieuwerts

http://www.w3.org/2001/XMLSchema#string

John A Foekens

http://www.w3.org/2001/XMLSchema#string

Jos Veldscholte

http://www.w3.org/2001/XMLSchema#string

Lambert C J Dorssers

http://www.w3.org/2001/XMLSchema#string

Marcel Smid

http://www.w3.org/2001/XMLSchema#string

Marion E Meijer-van Gelder

http://www.w3.org/2001/XMLSchema#string

Maxime P Look

http://www.w3.org/2001/XMLSchema#string

Stefan Sleijfer

http://www.w3.org/2001/XMLSchema#string

Ton van Agthoven

http://www.w3.org/2001/XMLSchema#string

P304

542-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3940062

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2008.17.1462

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23656175

http://www.w3.org/2001/XMLSchema#string

P698

19075277

http://www.w3.org/2001/XMLSchema#string

P921